U.S.-Based Perrigo Buying Elan For $8.6 Bil, Shifting Domicile To Ireland
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. generic drugmaker Perrigo agreed to buy Irish Elan for $8.6 billion in a deal that will hand it royalty rights from multiple sclerosis drug Tysabri and tax savings from being domiciled in Ireland.
You may also be interested in...
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.